Exclusive Market Study Cardiac Marker Analyzer Market will Grow at 4.5% CAGR During 2018-2026

According to the World Health Organization, 17.7 million deaths are reported every year due to cardiovascular diseases, which is estimated to be 31% of all the deaths throughout the globe. In the U.S., the prevalence of myocardial infraction is 3.3% and prevalence of angina pectoris in 4.5%, which is expected to increase over the forecast period. The rising prevalence of cardiovascular diseases is expected to fuel the growth of the global cardiac marker analyzer marketover the forecast period. According to the latest research by Persistence Market Research (PMR), the global cardiac marker analyzer market is projected to account for over US$ 959.6 Mn, in terms of value, by 2026 end. The report on the cardiac marker analyzer market further projects significant growth potential at a CAGR of 4.5% through 2026.

Cardiac marker analyzer enables rapid and real-time screening of the cardiovascular disorders such as heart failure, myocardial infraction and angina pectoris using cardiac biomarkers. Diagnostic information treatment decisions allow clinicians to reduce the likelihood of unnecessary adverse events. The importance of cardiac marker tests during the treatment of various cardiovascular disease is expected to fuel the growth of cardiac marker analyzer market over the forecast period.

Increasing burden of cardiovascular diseases, growing number of obese population and need for personalized real-time treatment and disease management regimens are projected to drive the growth of the cardiac marker analyzer market over the forecast period. Heart failure has become a global issue and is affecting more than 26 million people throughout the globe. The prevalence of heart failure is increasing rapidly due to growing geriatric population across the globe.Obesity has become the global health challenge in the past few decades, with every sixth person being obese. According to the WHO, the number of obese population around the globe has doubled in the last two decades. The WHO also estimated that 1.9 billion adults are suffering from overweight and of these over 650 are obese. This survey also estimated that around 13% of world adult population is suffering from obesity. Obesity is also associated with a number of cardiovascular diseases such congestive heart failure, angina pectoris and myocardial infarction. The rising obese population, which is at a high risk of developing cardiovascular diseases, is expected to consequently increase the demand for cardiac marker analyzer.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/3479
According to the National Institutes of Health (NIH), around 8.5% of the world population was aged 65 or above in 2016, and by 2050 this percentage is expected to grow to around 17%. Rise in geriatric population is also associated with increasing cardiovascular disorders such as heart failure, myocardial infraction and angina pectoris. Rise in geriatric population is expected to drive the cardiac marker analyzer market positively.

Persistence Market Research (PMR) has segmented the cardiac marker analyzer market based on product type, end user, and region.

By product type, the cardiac marker analyzer market is segmented into cardiac marker analyzer using immuno-fluorescence (IFA), cardiac marker analyzer using magnetic immuno-chromatographic assay (MICA), cardiac marker analyzer using chemiluminiscenece immunoassay (CLIA), cardiac marker analyzer using radioimmunoassay (RIA) and cardiac marker analyzer using enzyme immunoassay (EIA). Cardiac marker analyzer using chemiluminiscenece immunoassay (CLIA) are mostly used cardiac marker analyzer. Cardiac marker analyzer using chemiluminiscenece immunoassay (CLIA) is preferred due to its fast and accurate results.

North America and Europe are expected to be dominant regional markets for cardiac marker analyzer owing to favorable reimbursement coverage and increasing per capita healthcare expenditure. The Asia Pacific and Latin America cardiac marker analyzer markets are expected to witness significant growth due to active healthcare landscape and favorable government policies for startup companies.

Request TOC@ https://www.persistencemarketresearch.com/methodology/3479

The report tracks some of the key companies operating in the cardiac marker analyzer market, including Abbott Laboratories, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd., Siemens AG, Creative Diagnostics, Quidel Corporation, Radiometer Medical Aps, Boditech Med Inc., and Mitsubishi Chemical Europe GmbH.